Add to ORKGFor more than 50 years vitamin K antagonists (VKA) have been the gold standard for long-term oral anticoagulant treatment. New anticoagulants are now in extensive clinical development what will probably have a significant impact on daily practice in the near future. Compounds that specifically block activated factor X (FXa) or activated factor II (thrombin) have entered impressive phase III trials. Idraparinux is a long-active derivative from fondaparinux (synthetic pentasaccharide) and is administered subcutaneously. It inhibits indirectly FXa. Apixaban and rivaroxaban are small molecules that directly block FXa following oral administration. Dabigatran is another substance that is administered orally and directly inhibit thrombin. This ar...
Item does not contain fulltextUntil recently, vitamin K antagonists were the only available oral ant...
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blo...
Selective inhibitors of specific coagulation factors represent a new class of antithrombotic agents,...
Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists (...
For decades, oral Vitamin K Antagonists (VKA) have ruled the roost as anticoagulants. A narrow thera...
During the past five decades, anticoagulant therapy has consisted of rapidly acting parenteral drugs...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention ...
Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and atrial fibrillati...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Abstract—Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such...
Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists r...
Item does not contain fulltextUntil recently, vitamin K antagonists were the only available oral ant...
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blo...
Selective inhibitors of specific coagulation factors represent a new class of antithrombotic agents,...
Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists (...
For decades, oral Vitamin K Antagonists (VKA) have ruled the roost as anticoagulants. A narrow thera...
During the past five decades, anticoagulant therapy has consisted of rapidly acting parenteral drugs...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention ...
Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and atrial fibrillati...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Only after the elapse of over half-a-century of warfarin's reign are we witnessing significant progr...
Abstract—Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such...
Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists r...
Item does not contain fulltextUntil recently, vitamin K antagonists were the only available oral ant...
Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blo...
Selective inhibitors of specific coagulation factors represent a new class of antithrombotic agents,...
